Comparative Study of in vitro Anti-proliferative Activity of Metformin, Teneligliptin, and Canagliflozin against Breast Cancer Cell Line

ABSTRACT

Background: Cancer has become the second leading cause of death among the Indian population. Objectives: The purpose of the research was to elucidate and compare the suppressive impact on cell proliferation of metformin, teneligliptin, and canagliflozin on MCF-7 breast cancer cell lines. Materials and Methods: The MTT assay was employed to assess the anti-proliferative impact of the anti-diabetic drugs metformin, teneligliptin, and canagliflozin on MCF-7 breast cancer cell lines. After the MCF-7 cells achieved total growth, they were transferred to 24 well plates. Various quantities of metformin, teneligliptin, and canagliflozin were then administered to the appropriate wells. The maximum concentration was set at 1,000 μg/mL, but eight other concentrations were also set, with the lowest dosage being 7.8 μg/mL. Results: Through MTT assay, the cell viability of metformin was found to be 50.79, 48.77, 45.30, 41.40, 36.22, 29.35, 23.29, and 16.58% respectively. At concentrations of 7.8, 15.6, 31.2, 62.5, 125, 250, 500, and 1,000 μg/mL, the cell viability of teneligliptin was found to be 70.68, 63.79, 60.34, 50.48, 45.26, 41.37, 29.31, and 20.68%, respectively, and the cell viability of canagliflozin was found to be 72.28, 66.86, 51.96, 46.17, 40.34, 37.93, 34.38, and 27.58%, respectively. The inhibitory concentration 50 (IC50) values for metformin, canagliflozin, and teneligliptin were 7.8, 31.2, and 62.5 μg/mL, respectively. Conclusion: All the three selected anti-diabetic drugs produced significant anti-proliferative activity in a dose-dependent manner. Further studies are needed to find the molecular mechanism behind it.

KEYWORDS

• Anti-proliferative activity
• breast cancer
• metformin
• canagliflozin
• teneligliptin
• MTT assay

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.1177/0976500X251319832Copy

RELATED ARTICLES

Matched on volume, issue, section and article type within J Pharmacol. Pharmacother..

• Article · VOLUME 17, ISSUE 1Curcuma xanthorrhiza Rhizome Extract Attenuates the Complete Freund’s Adjuvantinduced Rheumatoid Arthritis in RatsPatrick A. Kalona, Uma Sundaresan, Chellappandian M., Ariharasivakumar G. · pp. 101–110Original Research ArticleSame type: ArticleSame issue
• Article · VOLUME 17, ISSUE 1A Comparative Study of Reno-protection with Combination of N-acetylcysteine and Keto Analogs Versus Probiotics and Keto Analogs in Predialytic Chronic Kidney DiseaseZeenath Unnissa, Umair Wahedi, Zeba Fatima, Mohammed Mudassir, Parthasaradhi Sarvepally · pp. 117–126Original Research ArticleSame type: ArticleSame issue
• Article · VOLUME 17, ISSUE 1Evaluation of Topical Lifitegrast Formulations for Treatment of PsoriasisRahul Sudhakar Gawande, Anil Meghrajji Pethe · pp. 127–134Original Research ArticleSame type: ArticleSame issue
• Article · VOLUME 17, ISSUE 1LungCTSeg-Net: Lung HRCT Image Segmentation Using Learning ApproachVanita Dnyandev Jadhav, Lalit Vasantrao Patil · pp. 135–144Original Research ArticleSame type: ArticleSame issue